BioCentury
ARTICLE | Company News

Emisphere, Novo Nordisk deal

November 16, 2015 8:00 AM UTC

Emisphere granted Novo Nordisk worldwide rights to develop and commercialize oral formulations of four classes of Novo’s products, including those for diabetes and obesity, using Emisphere’s oral Eligen technology. Emisphere granted Novo exclusive rights to three molecule classes and non-exclusive rights to a fourth class. Emisphere will receive $5 million up front and is eligible to receive up to $62.5 million in development and sales milestones for each exclusive molecule classes and up to $20 million in development milestones for the non-exclusive class. Emisphere is eligible for royalties. Novo is responsible for development and commercialization.

Novo also has an option for exclusive and non-exclusive rights to develop and commercialize additional products using Eligen for diabetes, obesity and other indications. Emisphere is eligible to receive an option exercise payment for each exclusive and non-exclusive molecule class. Emisphere is eligible to receive up to $62.5 million in development and sales milestones for each exclusive molecule class and up to $20 million in development milestones for the non-exclusive class, plus royalties. ...